Association of pregnancy with tumour progression in patients with glioma
- PMID: 39954413
- DOI: 10.1016/j.ejca.2025.115259
Association of pregnancy with tumour progression in patients with glioma
Abstract
Background: A significant proportion of women in reproductive age are diagnosed with diffuse gliomas, resulting in the need to address the safety of pregnancy in patient consultation. However, data on glioma progression after and during pregnancy are sparse and controversial.
Methods: Female adult patients in their reproductive years (≥18 years and <46 years) with histological diagnosis of glioma between 01/01/2000 and 01/12/2019 from 2 academic centers have been included in the study. Re-classification according to the 2021 WHO classification of CNS tumours was performed. The cohort was divided into 3 groups, defined as (A) nulliparae, (B) primi-/multiparae before glioma diagnosis, and (C) primi-/multiparae after glioma diagnosis. Survival analyses were performed in a time-dependent manner with parity as time-dependent covariate.
Results: 159/368 females met our inclusion criteria, resulting in 47 (29.6 %) nulliparae, 88 (55.3 %) primi-/multiparae before glioma diagnosis and 24 (15.1 %) primi-/multiparae after glioma diagnosis. Median follow-up was 127.4 months (range 0.7-341.9), and median overall survival and progression free survival were 247.6 months (range 0.4-269.1) and 67.9 months (range 0.7-341.9), respectively. Overall, 113/159 (71.1 %) patients had tumour progression and 53/159 (33.3 %) deceased. In total, 57.4 % of the nullipara, 76.1 % of the primi-/multipara before glioma diagnosis and 79.1 % of the primi-/multipara after glioma diagnosis groups experienced tumour progression (p > 0.05). In multivariate time-dependent analysis, primi-/multiparae after glioma diagnosis presented with shorter progression free (HR 2.45, p = 0.0079), but not overall survival (HR 0.54, p > 0.05) in comparison to the other two groups.
Conclusion: Pregnancy after glioma diagnosis was associated with shorter progression free survival. Longer follow-up as well as larger cohorts are needed to investigate a potential impact on overall survival.
Keywords: Fertility; Glioma; Outcome; Pregnancy; Progression free survival.
Copyright © 2025. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Zoltan Spiro is a previous employee of Boehringer Ingelheim and Turbine AI and a current employee of CBmed GmbH. Fransizka Eckert received Speaker's honoraria, travel costs of Dr. Sennewald Medizintechnik and advisory board partication from Servier. Georg Widhalm has received advisory board partication from Servier Annette Leibetseder has received honoraria for lectures, consultation or advisory board participation from UCB, Novocure, Servier and Telix as well as travel support from Roche, Novartis, Merz and Servier. Anna Sophie Berghoff has research support from Daiichi Sankyo, Roche and honoraria for lectures, consultation or advisory board participation from Roche Bristol-Meyers, Squibb, Merck, Daiichi Sankyio, AstraZeneca, CeCaVa, Seagen, Alexion, Servier as well as travel support from Roche, Amgen and AbbVie. Maximilian Mair has received research funding from Bristol-Myers Squibb and travel support from Pierre Fabre. Matthias Preusser has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Böhringer-Ingelheim, Telix, Medscape, OncLive. All remaining authors have declared no conflicts of interest.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
